Grifols, S.a.

Organisation

Parque Empresarial Can Sant Joan, Barcelona, Spain, 08174

Headquarters

25258

Employees

Health Technology

Industry

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Price

Target

Grifols, S.a. (GRFS) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Grifols, S.a. (GRFS) share price will touch around $12.53 in next 12-months.

Currently 22 wall-street analysts regularly analyze the financials of Grifols, S.a. on a frequent basis to provide recommendations along with target share price. 22 analysts offering 12-month price forecasts for Grifols, S.a. (GRFS) have a share price target of $12.53. This median of share price forecast represents a 65.46% upside from the latest price of $7.57 as on 23.03.26.

Grifols, S.a. (GRFS) Share Price Forecast

Home

US Stocks

Grifols, S.a. (GRFS)

Grifols, S.a. Stock Forecast

Grifols, S.a. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Grifols, S.a. (GRFS): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Grifols, S.a.'s share price and its median forecast price. As on 23.03.26, the difference is -29.82%

Grifols, S.a. Forecast and Target Price

Grifols, S.a. (GRFS) Share Price Forecast

Grifols, S.a. (GRFS) Price vs Consensus Price Target

Grifols, S.a. (GRFS) Share Price Forecast v/s Share Price Today

Grifols, S.a. (GRFS): Difference between Current Price & Median Forecasted Price

Grifols, S.a. (GRFS) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price